Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma.
Jiaxin HanWentao KuaiLiu YangXuemei TaoYuekui WangMinghui ZengYuqin LiYuqiang MiNing-Ning ZhangWei LuLiang XuPublished in: Cancer biology & medicine (2024)
ICI-based therapy in patients with CHB-related HCC and concurrent MASLD resulted in poorer efficacy and shorter PFS compared to patients with CHB-related HCC alone.